🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Abevmy 25 mg/mL concentrate for solution for infusion., CAPECITABINE VIATRIS 150 mg, comprimé pelliculé, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  2. Abiraterone Acetate

    United Therapeutics Europe Ltd

    Metastatic Castration Resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  3. Abiraterone acetate

    United Therapeutics Europe Ltd

    Prostate Cancer (Adenocarcinoma)

    phase 2 small molecule active

    1 trial

  4. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    The George Institute

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. Absorbable and moldable skull base support plate

    The First People's Hospital of Lianyungang

    Sellar Tumor

    phase 2 other active

    1 trial

  6. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  7. Acalabrutinib

    United Therapeutics Europe Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  9. Aceclidine+tropicamide combination

    LENZ Therapeutics

    Presbyopia

    phase 2 small molecule completed

    1 trial

  10. Active Comparator CT1812

    COGNITION THERAPEUTICS INC

    Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

  11. Active Treatment- CT1812 100 mg

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  12. Active cTBS

    United Therapeutics Europe Ltd

    Post-Concussion Syndrome

    phase 2 other active

    1 trial

  13. Active smoked cannabis

    Camp4 Therapeutics Corp

    Cannabis Smoking

    phase 2 small molecule active

    1 trial

  14. Active tDCS + task oriented practice

    United Therapeutics Europe Ltd

    Cervical Spinal Cord Injruy

    phase 2 other completed

    1 trial

  15. Active topical NS2 1% dermatologic cream

    Aldeyra Therapeutics

    Sjögren-Larsson Syndrome

    phase 2 small molecule completed

    1 trial

  16. Acupuncture

    United Therapeutics Europe Ltd

    Persian Gulf Syndrome

    phase 2 other completed

    1 trial

  17. Ad-HGF

    The First People's Hospital of Lianyungang

    Myocardial Infarction

    phase 2 small molecule active

    1 trial

  18. Ad-RTS-hIL-12

    Alaunos Therapeutics

    Metastatic Breast Cancer

    phase 2 mab terminated

    1 trial

  19. Ad-RTS-hIL-12

    Alaunos Therapeutics

    Pediatric Brain Tumor

    phase 2 mab terminated

    1 trial

  20. Ad-RTS-hIL-12

    Alaunos Therapeutics

    Glioblastoma

    phase 2 mab completed

    3 trials

  21. Ad-RTS-hIL-12 and Veledimex

    Alaunos Therapeutics

    Breast Cancer Nos Metastatic Recurrent

    phase 2 gene therapy terminated

    1 trial

  22. Adagrasib

    Partner Therapeutics Limited

    Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2

    phase 2 small molecule active

    1 trial

  23. AdaptNK –Cell Therapy for High-risk Myeloid Disease

    The George Institute

    Relapsed and/or refractory AML or MDS

    phase 2 other active

    1 trial

  24. Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources